Drug reference

talquetamab

Bispecific antibody

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

A bispecific antibody that binds to CD3 on human lymphocytes and GPRC5D (G protein–coupled receptor class C group 5) on myeloma cells, bringing T cells closer to myeloma cells to induce cell death.

Indications

Relapsed or refractory multiple myeloma

Related guidelines

Multifetal pregnancy

FOGSI · Obstetrics & Gynaecology · 2024

Generalised anxiety disorder and panic disorder

NICE · Psychiatry · 2020

Other Bispecific antibody drugs

Ask House about talquetamab

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Harrison 22e·Verified: 2026-05-10 · House clinical team